Collegium Pharmaceutical (COLL) Repositioning: Shifting Focus from Pain Management to ADHD

Yahoo Finance

Collegium Pharmaceutical is shifting its focus from pain management to ADHD, signaling a strategic repositioning in its business approach. The company's stock has experienced a decline, reflecting market reactions to this change in emphasis. The Third Avenue Small-Cap Value Fund's Q3 2026 performance highlights mixed contributions from various stocks, with Collegium Pharmaceuticals being a detractor.

Read at Yahoo Finance

All articles from 2 November 2026. Summaries are AI-generated and may contain errors; the linked article is the authority.

Get this news by email

Daily or as a weekly roundup in your inbox. You confirm your address first; every email has an unsubscribe link. For another topic or language, use the subscribe page.

More to read